NCT04047264

Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies

Recruiting now NA Last updated 12 February 2026

What this trial tests

NA trial testing Microdialysis in Glioma in 100 participants. Currently enrolling.

Timeline

1 January 2020

Primary endpoint
1 September 2027

1 September 2027

Quick facts

Lead sponsor	Mayo Clinic
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	100
Start date	1 January 2020
Primary completion	1 September 2027
Estimated completion	1 September 2027
Sites	1 location across United States

Drugs / interventions tested

• Microdialysis
• Magnetic Resonance Imaging

Conditions studied

• Glioma — all drugs for Glioma →
• Glioblastoma — all drugs for Glioblastoma →
• Metastatic Malignant Neoplasm in the Brain — all drugs for Metastatic Malignant Neoplasm in the Brain →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Glioma or Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial evaluates the use of microdialysis catheters during surgery to collect biomarkers, and studies the feasibility of intraoperative microdialysis during neurosurgery for central nervous system malignancies. A biomarker is a measurable indicator of the severity or presence of disease state. Information collected in this study may help doctors to develop new strategies to better diagnose, monitor, and treat brain tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Glioma Metabolic Feedback In Situ: A First-In-Human Pharmacodynamic Trial of Difluoromethylornithine + AMXT-1501 Through High-Molecular Weight Microdialysis.
   Riviere-Cazaux C, Neth BJ, Hoplin MD, Wessel B, et al · · 2023 · cited 13× · PMID 37246885 · DOI 10.1227/neu.0000000000002511
2. Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas.
   Riviere-Cazaux C, Carlstrom LP, Rajani K, Munoz-Casabella A, et al · · 2023 · cited 12× · PMID 37340056 · DOI 10.1038/s42003-023-05035-2
3. Unraveling the signaling mechanism behind astrocytoma and possible therapeutics strategies: A comprehensive review.
   Nahar Metu CL, Sutihar SK, Sohel M, Zohora F, et al · · 2023 · cited 9× · PMID 37675821 · DOI 10.1002/cnr2.1889
4. Advances in computational and translational approaches for malignant glioma.
   Bhargav AG, Domino JS, Alvarado AM, Tuchek CA, et al · · 2023 · cited 4× · PMID 37405133 · DOI 10.3389/fphys.2023.1219291
5. Methodological and analytical considerations for intra-operative microdialysis.
   Riviere-Cazaux C, Rajani K, Rahman M, Oh J, et al · · 2023 · cited 3× · PMID 38115038 · DOI 10.1186/s12987-023-00497-2
6. Window of opportunity evaluation of blood-brain barrier permeability heterogeneity within and across high-grade glioma patients.
   Oh JH, Reed SK, Riviere-Cazaux C, Kim M, et al · · 2026 · PMID 40916832 · DOI 10.1093/neuonc/noaf204
7. OS09.6.A A MULTICENTER, PHASE I/II, OPEN-LABEL STUDY OF INTRATHECAL PEMETREXED FOR LEPTOMENINGEAL METASTASES FROM SOLID TUMOR (PMLM, NCT 05289908)
   · 2023
8. OS09.4.A RANO 2.0: UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
   · 2023